LDN Medicine and Medication

Lodonal (LDN) works by boosting levels of endorphins (peptides produced in the brain and adrenal glands) that are best known for relieving pain and enhancing your sense of well-being. Endorphins are responsible for the “runner's high” brought on by strenuous exercise. These natural peptides are also powerful modulators of the immune system. 

Naltrexone has been used in 50 mg doses for decades to help patients recover from addiction to alcohol, heroin and other opiate drugs. However, more than 20 years ago it was discovered that very small doses of this drug—3 to 4.5 mg—have profound effects on the immune system.

How Does Low-Dose Naltrexone Work?

"Low-dose naltrexone (Lodonal or LDN) is a safe, inexpensive, yet underused drug that is extremely beneficial for people with conditions marked by immune system dysfunction.

When you take LDN Medication at bedtime, it attaches to opioid receptors in the brain and in all types of immune cells, which temporarily blocks endorphins from attaching to them. This signals your body to increase endorphin production. The increased endorphin production helps orchestrate the activity of stem cells, macrophages, natural killer cells, T and B cells and other immune cells.

It also prevents immune system overactivity, which is the crux of autoimmune disorders, and blunts the release of inflammatory and neurotoxic chemicals in the brain.

What Does Treatment With LDN Involve?

LDN Medicine requires a prescription and is available only from compounding pharmacies. (Regular pharmacies typically carry only 50 mg capsules.) The suggested dose is 3–4.5 mg per day, taken orally at bedtime.

The only contraindication is narcotic drugs. Low-dose naltrexone blocks the effects of narcotics and could cause withdrawal symptoms, so it should be started only after those drugs are completely out of your system.

LDN medication is safe and well tolerated. You may have vivid dreams at first, but sleep disturbances are rare. To avoid this, start with a dose of 1.5 mg and build up slowly over two months."

- Dr. Julian Whitaker

What Conditions Is LDN Good For?

NAFDAC Approval 

Immune Therapeutics, Inc. (OTCQB:IMUN) (the “Company”), a clinical-stage biotech company providing immunotherapy solutions for the treatment of autoimmune disease and cancer with a focus on emerging nations, today announced that Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) has approved its patented Lodonal as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune system regulator.

The receipt of NAFDAC’s approval will enable the Company’s distribution partner, AHAR Pharma, and GB Pharma Holdings, to launch a nationwide marketing and sales program that is expected to generate new and significant revenue channels for the Company.  The Company believes that this new sales revenue places it on-track towards achieving profitability and significant future revenue and earnings growth.

Phase III Trails: A number of phase I and phase II trials have shown Lodonal to benefit in the treatment of HIV/AIDS, cancer and autoimmune diseases. Where there is continued research with Lodonal until recently there was no one Biotech Company interested in completing phase III trials with Lodonal.  The body of research is growing rapidly, along with clinical experience and Lodonal certainly seems to work for many people. Which is why one small company Immune Therapeutics has moved forward with acquiring all of the patents and clinical work surrounding LDN so that they can obtain regulatory approval for LDN Medicine in emerging nations while Cytocom is working with the FDA and EMA for Lodonal approval in the United States and EU.